{
    "nct_id": "NCT02377713",
    "title": "A Phase 1 Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study of KHK6640 in Japanese Patients With Alzheimer's Disease.",
    "status": "COMPLETED",
    "last_update_time": "2016-12-06",
    "description_brief": "The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of KHK6640, given as a single dose in Japanese patients with Mild to Moderate Alzheimer's Disease.",
    "description_detailed": "N/A",
    "phase": [
        "PHASE1"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "TREATMENT",
    "results": null,
    "target_category": "disease-targeted biologic",
    "drug": [
        "KHK6640 (humanized anti-amyloid-\u03b2 oligomer-specific monoclonal antibody)"
    ],
    "placebo": [
        "placebo"
    ],
    "explanation_target": [
        "Reason: The trial drug KHK6640 is reported in the literature and trial registries as a humanized monoclonal antibody that selectively binds aggregated/oligomeric amyloid\u2011\u03b2 (A\u03b2) \u2014 i.e., an immunotherapeutic biologic directed at Alzheimer\u2019s pathology. This indicates a disease\u2011targeting biologic intended to modify pathology rather than a small molecule or symptomatic cognitive enhancer. \ue200cite\ue202turn0search1\ue202turn0search0\ue201",
        "Act: Key extracted details from web sources \u2014 (1) KHK6640 is described as an oligomer\u2011specific anti\u2011A\u03b2 humanized monoclonal antibody; (2) the study is a Phase 1 randomized, double\u2011blind, placebo\u2011controlled, single ascending dose study in Japanese patients with mild\u2011to\u2011moderate Alzheimer\u2019s disease sponsored by Kyowa Hakko Kirin; (3) Phase 1/2 data and summaries report safety, pharmacokinetics, CSF target engagement and exploratory biomarker/cognition outcomes. \ue200cite\ue202turn0search1\ue202turn0search3\ue202turn0search6\ue201",
        "Reflect: Classification check \u2014 the intervention is a biologic (monoclonal antibody) targeting A\u03b2 oligomers (disease pathology). This fits the definition of \"disease\u2011targeted biologic.\" There is no indication it is a small molecule, a purely symptomatic cognitive enhancer, or an agent aimed primarily at neuropsychiatric symptoms, so the assigned category is appropriate. \ue200cite\ue202turn0search7\ue202turn0search0\ue201",
        "Web search results (selected):",
        "- PubMed abstract describing KHK6640 as a novel humanized anti\u2011amyloid\u2011\u03b2 oligomer\u2011specific antibody and reporting Phase I/IIa safety, PK and exploratory biomarker/cognition results. \ue200cite\ue202turn0search1\ue201",
        "- Springer / Journal of Prevention of Alzheimer\u2019s Disease article reporting Phase 1/2a intravenous and subcutaneous KHK6640 trials and noting oligomer\u2011specific antibody design and biomarker effects. \ue200cite\ue202turn0search0\ue201",
        "- Clinical trial record (Kyowa Hakko Kirin) for the Phase 1 single ascending dose study in Japanese patients confirming study title, design, sponsor and population. \ue200cite\ue202turn0search3\ue201",
        "Notes/uncertainty: None material \u2014 sources consistently identify KHK6640 as an anti\u2011A\u03b2 oligomer monoclonal antibody developed by Kyowa Hakko Kirin, so the trial clearly falls into the \"disease\u2011targeted biologic\" category. \ue200cite\ue202turn0search1\ue202turn0search6\ue201"
    ],
    "agent_type": "A) Amyloid beta",
    "explanation_agent": [
        "Reason: The investigational product KHK6640 is described in multiple sources as a humanized monoclonal antibody that selectively binds aggregated/oligomeric forms of amyloid\u2011\u03b2 (A\u03b2), i.e., an immunotherapeutic biologic directed at A\u03b2 pathology rather than a symptomatic target. \ue200cite\ue202turn0search2\ue202turn0search1\ue202turn0search0\ue201",
        "Act: Extracted details \u2014 (1) Drug: KHK6640, a humanized anti\u2011A\u03b2 oligomer\u2011specific monoclonal antibody; (2) Sponsor/designer: Kyowa Hakko Kirin (licensed from Immunas/related development history); (3) Trial design: Phase 1 randomized, double\u2011blind, placebo\u2011controlled single (and related multi) ascending dose studies in AD patients; (4) Reported outcomes: safety, PK, CSF target engagement and exploratory biomarker/cognition signals. \ue200cite\ue202turn0search2\ue202turn0search3\ue202turn0search4\ue202turn0search1\ue201",
        "Reflect: Classification check \u2014 because the molecule is an antibody whose stated mechanism is selective binding/removal (or sequestration) of aggregated/oligomeric A\u03b2, the correct CADRO category is A) Amyloid beta. There is no indication the primary mechanism targets tau, inflammation, synaptic receptors, metabolism, or a multi\u2011target strategy, so 'A) Amyloid beta' is the most specific fit. \ue200cite\ue200cite\ue202turn0search7\ue202turn0search5\ue201",
        "Web search results (selected): - PubMed: Phase 1/2a study abstract describing KHK6640 as a novel humanized anti\u2011A\u03b2 oligomer\u2011specific antibody and reporting safety, PK and exploratory biomarker/cognition results. \ue200cite\ue202turn0search2\ue201 - Springer / Journal of Prevention of Alzheimer\u2019s Disease: Phase 1/2a article reporting IV and SC KHK6640 trials and noting oligomer\u2011specific design and biomarker effects. \ue200cite\ue202turn0search1\ue201 - Kyowa Hakko Kirin press release: announcement of Phase I development of an antibody selective for aggregated A\u03b2. \ue200cite\ue202turn0search0\ue201 - Clinical trial registry records (Japanese and multinational Phase 1 trials; single and multiple ascending dose studies) confirming study titles, design, sponsor and timelines. \ue200cite\ue202turn0search3\ue202turn0search4\ue201 - Alzforum coverage summarizing antibody design (IgG4 with reduced effector function) and trial safety/biomarker observations. \ue200cite\ue202turn0search7\ue201",
        "Output: Assigned category \u2014 A) Amyloid beta. Brief justification: KHK6640 is an oligomer\u2011specific anti\u2011A\u03b2 humanized monoclonal antibody (disease\u2011targeting biologic) and therefore fits CADRO category A. \ue200cite\ue202turn0search2\ue202turn0search1\ue201"
    ]
}